ArriVent BioPharma (AVBP) Interest Expenses (2023 - 2026)

ArriVent BioPharma (AVBP) has 4 years of Interest Expenses data on file, last reported at $40.1 million in Q1 2026.

• For the quarter ending Q1 2026, Interest Expenses rose 35.65% year-over-year to $40.1 million; the trailing twelve-month figure through Mar 2026 stood at $40.1 million (up 35.65% YoY), and the FY2025 full-year result was $31.7 million, down 37.09% from the prior year.
• Interest Expenses advanced to $40.1 million in Q1 2026, from $168000.0 in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $44.1 million in Q4 2023 to a low of $168000.0 in Q4 2025.
• A 4-year average of $28.9 million and a median of $33.0 million in 2024 frame the typical range for Interest Expenses.
• Across the five-year window, Interest Expenses slumped 99.46% in 2024 and soared 35.65% in 2026, its largest moves.
• Tracing AVBP's Interest Expenses over 4 years: stood at $44.1 million in 2023, then tumbled by 99.46% to $239000.0 in 2024, then dropped by 29.71% to $168000.0 in 2025, then soared by 23739.88% to $40.1 million in 2026.
• Business Quant data shows AVBP's Interest Expenses at $40.1 million in Q1 2026, $168000.0 in Q4 2025, and $28.5 million in Q3 2025.